With over 25 years of experience across both large pharma (Pfizer, Eisai, Takeda, Mundipharma) and smaller biotech companies, Tim has established a strong track record in clinical design, regulatory strategy, business development and leadership, progressing multiple compounds through clinical trials to market in several therapeutic

areas. Within hepatology, Tim successfully led the development of avatrombopag, including the design of two innovative pivotal phase 3 studies resulting in global approvals. In addition, he has previously worked on MASH and viral hepatitis programs and also rare/orphan liver diseases, such as Primary Sclerosing Cholangitis and Wilson’s Disease